UBS Maintains Neutral on Amrize, Lowers Price Target to $42
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
UBS analyst Julian Radlinger maintains Amrize (NYSE:AMRZ) with a Neutral and lowers the price target from $57 to $42.
UBS analyst Julian Radlinger maintains Amrize (NYSE:AMRZ) with a Neutral and lowers the price target from $57 to $42.